Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1045 results
June 2019
-
Media ReleaseThree quarters of people living with axial spondyloarthritis struggle to find a job, IMAS survey showsNew European data from IMAS survey show that people living with axial spondyloarthritis (axSpA) suffer a delay in diagnosis of over 7 years, potentially leading to an increase in work-related…
-
Media ReleaseCosentyx® provides long-lasting inhibition of radiographic progression in psoriatic arthritis, new Novartis data showAlmost 90% of patients had no radiographic progression of psoriatic arthritis (PsA) at 2 years with Cosentyx (secukinumab) 300mg[1] Data at 2 years demonstrate over 50% of adults with…
-
Media ReleaseNovartis Cosentyx® first to show efficacy in all key manifestations of psoriatic arthritisFirst-of-its-kind data shows efficacy and safety of a biologic in the management of axial manifestations of psoriatic arthritis (PsA), which affect up to an estimated 35 million people worldwide[1…
-
Key ReleaseNovartis announces new leader of Pharmaceuticals Business UnitMarie-France Tschudin, an experienced Novartis leader, appointed to President, Novartis Pharmaceuticals Basel, June 7, 2019 - Novartis announced today that Marie-France Tschudin, currently…
-
Media ReleaseAdvanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare®Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare® for Reduction of Kidney Exposure to Radiation During Peptide Receptor Radionuclide Therapy with Lutetium (177Lu)…
-
Media ReleaseNovartis presents first-of-its-kind histology data with iscalimab (CFZ533) suggesting the extended survival of transplanted organs may be possibleData show 60% of iscalimab-treated transplant patients have normal kidney histology at least 1 year after transplant vs 0% with tacrolimus (current standard of care)[1] Less than half of donated…
-
Media ReleaseLong-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar® + Mekinist®Five-year Tafinlar + Mekinist survival data presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting and published simultaneously in The New England Journal of Medicine…
-
Media ReleaseNovartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical TrialsPrimary analysis of investigational capmatinib (INC280) in the GEOMETRY mono-1 study demonstrates promising efficacy in patients with locally advanced or metastatic non-small cell lung cancer (…
-
Media ReleaseXolair® (omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studiesIn the phase III POLYP 1 and POLYP 2 studies, omalizumab met both co-primary endpoints and key secondary endpoints in adults with chronic rhinosinusitis with nasal polyps (CRSwNP) with inadequate…
-
Media ReleaseNovartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trialKisqali is the only CDK4/6 inhibitor to show superior overall survival in advanced breast cancer (HR=0.712; p=0.00973)[1] After a median of 42 months follow-up, the survival rate was 70.2% for…
May 2019
-
Media ReleaseNovartis' phase III QUARTZ study of new investigational inhaled combination treatment QMF149 meets primary and key secondary endpoints in patients with inadequately controlled asthmaLow dose QMF149 (indacaterol acetate and mometasone furoate) demonstrated both statistically significant and clinically meaningful improvements in lung function and asthma control compared to…
-
Key ReleaseFDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancerPiqray (alpelisib, formerly BYL719) plus fulvestrant nearly doubled median PFS (11.0 vs 5.7 months) in HR+/HER2- advanced breast cancer patients with a PIK3CA mutation compared to fulvestrant alone…
Pagination
- ‹ Previous page
- 1
- …
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- …
- 88
- › Next page